(see earlier workshops below)
IPECAD modeling workshop 4 – 2023
Save the date: 4th IPECAD Modeling Workshop – AD model cross comparison (13-14 April, 2023)
Save the date: IPECAD Modeling Workshop, 13-14 April, 2023, face-to-face meeting (followed by a virtual meeting for those who cannot attend the face-to-face meeting).
Location: on site in Europe, venue to be determined.
We are pleased to announce the 4th upcoming IPECAD modeling workshop on modeling methods aligned to the health policy context for Alzheimer’s disease (AD) and related dementias.
The aim of this IPECAD 2023 modeling workshop is to improve the transparency and understanding of health economic models in the context of the effect of AD interventions. This will be accomplished by comparing predictions from a set of submitted models that have implemented the same disease-modifying AD drug trial outcomes. The workshop will include a discussion of differences across model results in relation to factors such as model design, parameterization, and model assumptions. Before the workshop takes place, a reference case benchmark scenario and a standardized output form will be developed by the organizing committee and shared for comments with all participants.
Let us know you are interested, leave your contact details: https://docs.google.com/forms/d/1HtkV7IYvD82hbav1DGT8fwFjth6KUm99r2dBRaCxlTI/edit?usp=sharing
The specific focus of this 4th workshop edition is on the overall challenge of using trial outcomes in a decision model, and specifically of selecting outcomes from short-term detailed trial efficacy evidence and translating them to long-term patient-relevant outcomes in a decision analytic framework. For this, we will mimic the outcomes of a hypothetical DMT trial in terms of synthetic individual patient level as well as aggregated data on surrogate, symptom and biomarker outcomes over a 2-year time period both for a control (placebo) and intervention arm (hypothetical DMT) in an MCI due to AD population in a U.S. setting. This contrasts the previous cross-comparison workshop in 2020 where only a general efficacy statement was provided.
We plan to hold 2 meetings: a face-to-face meeting and subsequently a virtual meeting for those who cannot attend the face-to-face meeting. If you are interested or wish to be updated on this workshop, please indicate your interest using the link above. More information on the 4th workshop will follow.
IPECAD modelling workshop 3 – 2021
Agenda and minutes
IPECAD modelling workshop – network meeting 2021, September (virtual).
We are pleased to announce the next IPECAD modelling workshop.
We aim to host a network meeting on decision modelling in Alzheimer’s disease and related dementias to provide an update of former workshop members on modelling developments, to hear from invited external speakers on the value of model outcomes cross-comparison, and share a plan for the modelling cross-comparison workshop aimed for 2022. See program details below.
Let us konw you are intrested
Since we have limited spaces available, we would like to invite those with an active role in decision modelling in the field of Alzheimer’s disease. Please use the following link to leave your contact details and background information to apply for the workshop:
[16-09-2021: applications closed, link no longer available]
With best regards,
On behalf of the organizing committee, IPECAD Modelling Group
IPECAD modelling workshop 2 – 2020
The results of the workshop can be found here (https://doi.org/10.1002/alz.12811):
Benchmark scenario, working procedures, agenda
Comparison of Cost-Effectiveness/Disease Progression (Health Economic) Models in Alzheimer’s Disease – NETWORK Meeting, 2020
Trust and confidence are critical to the successful use of decision-analytic health care models. The aim of this meeting is to improve the transparency and trust aligned to use of health economic models in the context of Alzheimer’s disease (AD). This will be achieved through ongoing development of methods, improved reporting standards, and related good practice within the field of decision-analytic modelling in the area of AD. The key objective of this upcoming meeting is to receive submissions on AD modelling aligned to the challenge/scenarios set out, and to systematically examine cross-model differences in predicted outcomes, with structured discussion in relation to model design choices and parameterization. The meeting is based on a reference case benchmark scenario (and requested output matrix) – developed through prior discussion – that can be run in multiple health economic models of Alzheimer’s Disease (AD), and which will allow comparison of model predictions and facilitate identification of possible factors explaining the range of and heterogeneity across modelling and simulation outcomes.
IPECAD modelling workshop 1 – 2019
Agenda and minutes
AD Modelling Workshop, 19th-20th September, 2019, Stockholm, Sweden.
The IPECAD modelling group is planning an upcoming inaugural IPECAD workshop on modelling methods aligned to the health policy context for Alzheimer’s disease. This workshop is invitation only, and aimed at people who are research active in this area, and those in close collaborations with people/teams who are research active in this area.
In this workshop we wish to bring together people who are active in the area of Alzheimer’s disease decision-modelling, and who are developing modelling methods in the context of cost-effectiveness analyses and health technology assessment, or disease progression models that may be used in this way.
We plan for this workshop to be the first of a future series of meetings and activities to further the development of modelling methods, and the identification of data to populate decision-models, in the area of Alzheimer’s disease (AD). Whilst the initial focus is on AD, we hope to be able to extend the scope of our future activity into and across related dementias, and across the full diagnostic and treatment pathways associated with dementia.
We aim to increase understanding of modelling methods in the area of Alzheimer’s disease and to facilitate methodological development, transparency and comparability, with a view to further developing methods available to support the ambition of rapid access to effective and cost-effective care for people affected by AD, and related dementias.
On behalf of the IPECAD Modelling Group
Dr. Linus Jönsson – Karolinska Institutet, Sweden; H. Lundbeck A/S, Denmark,
Prof. Colin Green – University of Exeter, UK,
Dr. Ron Handels – Karolinska Institutet, Sweden; Maastricht University, Netherlands
Prof. Bengt Winblad – Karolinska Institutet, Sweden
Prof. Anders Wimo – Karolinska Institutet, Sweden
Dr. Anders Gustavsson – Karolinska Institutet, Sweden; Quantify Research, Sweden
Dr. Anders Sköldunger – Karolinska Institutet, Sweden